Exelixis(US:EXEL)2025-11-04 21:25Financial Performance - Total revenues for Q3 2025 were $597.8 million, up from $539.5 million in Q3 2024, representing an increase of approximately 10.5%[3] - U.S. net product revenues from the cabozantinib franchise were $542.9 million, compared to $478.1 million in the same period last year, reflecting a growth of about 13.5%[3] - GAAP net income for Q3 2025 was $193.6 million, or $0.69 per diluted share, compared to $118.0 million, or $0.40 per diluted share in Q3 2024, marking a year-over-year increase of 64%[9] - Non-GAAP net income for Q3 2025 was $217.9 million, or $0.78 per diluted share, compared to $135.7 million, or $0.47 per diluted share in Q3 2024, indicating a growth of approximately 60.6%[10] - Total revenues for the nine months ended September 30, 2025, reached $1.72 billion, compared to $1.60 billion for the same period in 2024, reflecting a 7.5% growth[34] - The company’s net income for Q3 2025 was $193.58 million, up 64.2% from $117.97 million in Q3 2024[34] Expenses - Research and development expenses decreased to $199.2 million in Q3 2025 from $222.6 million in Q3 2024, a reduction of about 10.5%[5] - Selling, general and administrative expenses increased to $123.7 million in Q3 2025 from $111.8 million in Q3 2024, an increase of approximately 10.5%[6] - The company’s operating expenses for Q3 2025 totaled $361.22 million, a decrease from $403.47 million in Q3 2024[34] Stock and Shareholder Returns - Exelixis announced an additional stock repurchase program for up to $750 million by the end of 2026[1] - Exelixis has repurchased $895.3 million of its common stock at an average price of $37.18 per share as of September 30, 2025, returning $1.9 billion to shareholders since March 2023[24] - The weighted-average diluted common shares outstanding decreased from 326.3 million to 278.5 million shares since the first stock repurchase program in March 2023[24] Future Plans and Guidance - Exelixis is providing updated financial guidance for 2025, projecting total revenues between $2.30 billion and $2.35 billion[15] - The company plans to submit a New Drug Application for zanzalintinib in combination with atezolizumab for advanced colorectal cancer by the end of 2025[18] - Exelixis plans to submit a New Drug Application for zanzalintinib in combination with atezolizumab by the end of 2025, pending government service availability[30] Pipeline Development - The cabozantinib franchise generated $542.9 million in net product revenues, with $46.3 million earned in royalty revenues from collaboration partners[16] - Exelixis initiated a phase 1 study of XB371 in August 2025, expanding its early-stage pipeline programs to four ongoing phase 1 trials[23] - Exelixis estimates a federal cash tax benefit of $147 million from the repeal of the requirement to capitalize domestic R&E expenditures, effective for taxable years beginning after December 31, 2024[25]